RU-58642

RU-58642
Systematic (IUPAC) name
4-[3-(cyanomethyl)-4,4-dimethyl-2,5-dioxoimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Identifiers
CAS Number 143782-63-2
PubChem CID 9840708
ChemSpider 8016425
Chemical data
Formula C15H11F3N4O2
Molar mass 336.268 g/mol

RU-58642 is a non-steroidal anti-androgen drug with very high affinity and selectivity, which made it among the most potent and effective antiandrogen drugs known at the time of its discovery.[1] It was investigated for topical application for the treatment of baldness, but development did not proceed past initial trial stages, and it is now only used for scientific research into the androgen receptor.[2][3]

References

  1. Battmann, T.; Branche, C.; Bouchoux, F.; Cerede, E.; Philibert, D.; Goubet, F.; Teutsch, G.; Gaillard-Kelly, M. (1998). "Pharmacological profile of RU 58642, a potent systemic antiandrogen for the treatment of androgen-dependent disorders". The Journal of Steroid Biochemistry and Molecular Biology 64 (1–2): 103–111. doi:10.1016/S0960-0760(97)00151-9. PMID 9569015.
  2. Sims, N. A.; Clément-Lacroix, P.; Minet, D.; Fraslon-Vanhulle, C.; Gaillard-Kelly, M.; Resche-Rigon, M. L.; Baron, R. (2003). "A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor–deficient mice". Journal of Clinical Investigation 111 (9): 1319–1327. doi:10.1172/JCI17246. PMC 154447. PMID 12727923.
  3. Windahl, S. H.; Galien, R.; Chiusaroli, R.; Clément-Lacroix, P.; Morvan, F.; Lepescheux, L. N.; Nique, F. O.; Horne, W. C.; Resche-Rigon, M. L.; Baron, R. (2006). "Bone protection by estrens occurs through non–tissue-selective activation of the androgen receptor". Journal of Clinical Investigation 116 (9): 2500–2509. doi:10.1172/JCI28809. PMC 1555662. PMID 16955145.
This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.